Ascentage Pharma Group International - American Depository Shares (AAPG)

Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company that discovers and develops therapies for cancers, chronic hepatitis B and age-related diseases. Its research centers on inhibiting proteins involved in apoptosis, or programmed cell death, such as the BCL-2 family, as well as kinase inhibitors for blood cancers.

Its lead approved product is olverembatinib, a third-generation BCR-ABL inhibitor used in chronic myeloid leukemia, including cases with the T315I mutation. Another key candidate is lisaftoclax, a BCL-2 inhibitor being studied in chronic lymphocytic leukemia and other hematologic malignancies. The company also has additional clinical programs in solid and blood cancers.

Ascentage Pharma is headquartered in Suzhou, China, and also has operations in the United States. Its shares are listed in Hong Kong, and its American depositary shares began trading on Nasdaq in 2025.